Cargando…

Preoperative identification of clinicopathological prognostic factors for relapse-free survival in clinical N1 non-small cell lung cancer: a retrospective single center-based study

BACKGROUND: Given the difficulty in preoperatively diagnosing lymph node metastasis, patients with Stage I–III non-small cell lung cancer (NSCLC) are likely to be included in the clinical N1 (cN1) group. However, better treatment options might be selected through further stratification. This study a...

Descripción completa

Detalles Bibliográficos
Autores principales: Aragaki, Masato, Kato, Tatsuya, Fujiwara-Kuroda, Aki, Hida, Yasuhiro, Kaga, Kichizo, Wakasa, Satoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456382/
https://www.ncbi.nlm.nih.gov/pubmed/32859238
http://dx.doi.org/10.1186/s13019-020-01272-2
_version_ 1783575786811293696
author Aragaki, Masato
Kato, Tatsuya
Fujiwara-Kuroda, Aki
Hida, Yasuhiro
Kaga, Kichizo
Wakasa, Satoru
author_facet Aragaki, Masato
Kato, Tatsuya
Fujiwara-Kuroda, Aki
Hida, Yasuhiro
Kaga, Kichizo
Wakasa, Satoru
author_sort Aragaki, Masato
collection PubMed
description BACKGROUND: Given the difficulty in preoperatively diagnosing lymph node metastasis, patients with Stage I–III non-small cell lung cancer (NSCLC) are likely to be included in the clinical N1 (cN1) group. However, better treatment options might be selected through further stratification. This study aimed to identify preoperative clinicopathological prognostic and stratification factors for patients with cN1 NSCLC. METHODS: This retrospective study evaluated 60 patients who were diagnosed with NSCLC during 2004–2014. Clinical nodal status had been evaluated using routine chest computed tomography (CT) and/or positron emission tomography (PET). To avoid biasing the fluorodeoxyglucose uptake values based on inter-institution or inter-model differences, we used only two PET systems (one PET system and one PET/CT system). Relapse-free survival (RFS) and overall survival (OS) were the primary study outcomes. The maximum standardized uptake value (SUVmax) was calculated for each tumor and categorized as low or high based on the median value. Patient sex, age, histology, tumor size, and tumor markers were also assessed. RESULTS: Poor OS was associated with older age (P = 0.0159) and high SUVmax values (P = 0.0142). Poor RFS was associated with positive carcinoembryonic antigen (CEA) expression (P = 0.0035) and high SUVmax values (P = 0.015). Multivariate analyses confirmed that poor OS was independently predicted by older age (hazard ratio [HR] = 2.751, confidence interval [CI]: 1.300–5.822; P = 0.0081) and high SUVmax values (HR = 5.121, 95% CI: 1.759–14.910; P = 0.0027). Furthermore, poor RFS was independently predicted by positive CEA expression (HR = 2.376, 95% CI: 1.056–5.348; P = 0.0366) and high SUVmax values (HR = 2.789, 95% CI: 1.042–7.458; P = 0.0410). The primary tumor’s SUVmax value was also an independent prognostic factor for both OS and RFS. CONCLUSIONS: For patients with cN1 NSCLC, preoperative prognosis and stratification might be performed based on CEA expression, age, and the primary tumor’s SUVmax value. To enhance the prognostic value of the primary tumor’s SUVmax value, minimizing bias between facilities and models could lead to a more accurate prognostication.
format Online
Article
Text
id pubmed-7456382
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74563822020-08-31 Preoperative identification of clinicopathological prognostic factors for relapse-free survival in clinical N1 non-small cell lung cancer: a retrospective single center-based study Aragaki, Masato Kato, Tatsuya Fujiwara-Kuroda, Aki Hida, Yasuhiro Kaga, Kichizo Wakasa, Satoru J Cardiothorac Surg Research Article BACKGROUND: Given the difficulty in preoperatively diagnosing lymph node metastasis, patients with Stage I–III non-small cell lung cancer (NSCLC) are likely to be included in the clinical N1 (cN1) group. However, better treatment options might be selected through further stratification. This study aimed to identify preoperative clinicopathological prognostic and stratification factors for patients with cN1 NSCLC. METHODS: This retrospective study evaluated 60 patients who were diagnosed with NSCLC during 2004–2014. Clinical nodal status had been evaluated using routine chest computed tomography (CT) and/or positron emission tomography (PET). To avoid biasing the fluorodeoxyglucose uptake values based on inter-institution or inter-model differences, we used only two PET systems (one PET system and one PET/CT system). Relapse-free survival (RFS) and overall survival (OS) were the primary study outcomes. The maximum standardized uptake value (SUVmax) was calculated for each tumor and categorized as low or high based on the median value. Patient sex, age, histology, tumor size, and tumor markers were also assessed. RESULTS: Poor OS was associated with older age (P = 0.0159) and high SUVmax values (P = 0.0142). Poor RFS was associated with positive carcinoembryonic antigen (CEA) expression (P = 0.0035) and high SUVmax values (P = 0.015). Multivariate analyses confirmed that poor OS was independently predicted by older age (hazard ratio [HR] = 2.751, confidence interval [CI]: 1.300–5.822; P = 0.0081) and high SUVmax values (HR = 5.121, 95% CI: 1.759–14.910; P = 0.0027). Furthermore, poor RFS was independently predicted by positive CEA expression (HR = 2.376, 95% CI: 1.056–5.348; P = 0.0366) and high SUVmax values (HR = 2.789, 95% CI: 1.042–7.458; P = 0.0410). The primary tumor’s SUVmax value was also an independent prognostic factor for both OS and RFS. CONCLUSIONS: For patients with cN1 NSCLC, preoperative prognosis and stratification might be performed based on CEA expression, age, and the primary tumor’s SUVmax value. To enhance the prognostic value of the primary tumor’s SUVmax value, minimizing bias between facilities and models could lead to a more accurate prognostication. BioMed Central 2020-08-28 /pmc/articles/PMC7456382/ /pubmed/32859238 http://dx.doi.org/10.1186/s13019-020-01272-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Aragaki, Masato
Kato, Tatsuya
Fujiwara-Kuroda, Aki
Hida, Yasuhiro
Kaga, Kichizo
Wakasa, Satoru
Preoperative identification of clinicopathological prognostic factors for relapse-free survival in clinical N1 non-small cell lung cancer: a retrospective single center-based study
title Preoperative identification of clinicopathological prognostic factors for relapse-free survival in clinical N1 non-small cell lung cancer: a retrospective single center-based study
title_full Preoperative identification of clinicopathological prognostic factors for relapse-free survival in clinical N1 non-small cell lung cancer: a retrospective single center-based study
title_fullStr Preoperative identification of clinicopathological prognostic factors for relapse-free survival in clinical N1 non-small cell lung cancer: a retrospective single center-based study
title_full_unstemmed Preoperative identification of clinicopathological prognostic factors for relapse-free survival in clinical N1 non-small cell lung cancer: a retrospective single center-based study
title_short Preoperative identification of clinicopathological prognostic factors for relapse-free survival in clinical N1 non-small cell lung cancer: a retrospective single center-based study
title_sort preoperative identification of clinicopathological prognostic factors for relapse-free survival in clinical n1 non-small cell lung cancer: a retrospective single center-based study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456382/
https://www.ncbi.nlm.nih.gov/pubmed/32859238
http://dx.doi.org/10.1186/s13019-020-01272-2
work_keys_str_mv AT aragakimasato preoperativeidentificationofclinicopathologicalprognosticfactorsforrelapsefreesurvivalinclinicaln1nonsmallcelllungcanceraretrospectivesinglecenterbasedstudy
AT katotatsuya preoperativeidentificationofclinicopathologicalprognosticfactorsforrelapsefreesurvivalinclinicaln1nonsmallcelllungcanceraretrospectivesinglecenterbasedstudy
AT fujiwarakurodaaki preoperativeidentificationofclinicopathologicalprognosticfactorsforrelapsefreesurvivalinclinicaln1nonsmallcelllungcanceraretrospectivesinglecenterbasedstudy
AT hidayasuhiro preoperativeidentificationofclinicopathologicalprognosticfactorsforrelapsefreesurvivalinclinicaln1nonsmallcelllungcanceraretrospectivesinglecenterbasedstudy
AT kagakichizo preoperativeidentificationofclinicopathologicalprognosticfactorsforrelapsefreesurvivalinclinicaln1nonsmallcelllungcanceraretrospectivesinglecenterbasedstudy
AT wakasasatoru preoperativeidentificationofclinicopathologicalprognosticfactorsforrelapsefreesurvivalinclinicaln1nonsmallcelllungcanceraretrospectivesinglecenterbasedstudy